Joey Solitro
Medicare's efforts to get drugmakers to reduce prices of the first 10 Part D drugs selected under the Medicare Drug Price Negotiation Program are progressing.
The 10 drugmakers participating in the talks sent counteroffers to the agency earlier this week, following its initial offer on February 1.
“We are committed to constructive dialogue and are glad the drug companies are coming to the table,” Xavier Becerra, secretary of the Health and Human Services Department, said in a statement. “These are good-faith, up-front negotiations. The Biden-Harris Administration is working to lower costs for families and keep money in the pockets of millions of Americans instead of Big Pharma.”
From just $107.88 $24.99 for Kiplinger Personal Finance
Be a smarter, better informed investor.
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Negotiations are slated to end August 1.The new negotiated prices for the drugs are expected to be announced by September 1, with an effective date of January 2026.
Medicare — the country’s largest prescription drug buyer — intends to choose up to 60 more drugs for the program during the next four years and up to 20 additional drugs per year after that.
Drugmakers participating in the talks are: AstraZeneca AB; Boehringer Ingelheim; Bristol Myers Squibb; Immunex; Janssen Biotech; Janssen Pharmaceuticals; Merck & Co.; Novartis Pharmaceuticals; Novo Nordisk; and Pharmacyclics.
Medicare selected the first 10 drugs for the program last year. The drugs, covered under Part D, are: Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara and Fiasp/NovoLog.
In 2022, about 9 million Medicare beneficiaries were prescribed the drugs selected for this first round of the program. Some of these seniors were paying nearly $6,500 in out-of -pocket costs for just one of the drugs, President Joe Biden said in a February 1 announcement about the progress of negotiations.
In January, drugmakers raised prices on six of the 10 the drugs even after all 10 were priced 3- to 8-times higher in the U.S, than in other countries, the administration said.
Under the program, which is authorized under the Inflation Reduction Act, Medicare has the authority for the first time to directly negotiate prices for certain high-cost, single-source drugs that do not have generic or biosimilar competition.
“This is the first time ever that Medicare is not accepting the drug prices the pharmaceutical companies set,” the administration said.
By contrast, it added, Medicaid, the Department of Defense and the Veterans Health Administration already had the authority to negotiate drug prices and they pay less than Medicare, on average, for top-selling, brand-name drugs.
$79,000 vs. $16,000 for Stelara
Drugmakers, which have filed a total of nine lawsuits attempting to block the Medicare Drug Price Negotiation Program, remain under fire on and off Capitol Hill for charging exorbitantly higher prices in the U.S. than in other countries.
That situation was the focus of a Senate committee hearing last month when executives from Johnson & Johnson, Merck and Bristol Myers Squibb were grilled.
In the U.S., Johnson & Johnson charges $79,000 for arthritis medicine Stelara, while that same product can be purchased for $16,000 in the U.K., Sen. Bernie Sanders (I-VT) said during the hearing.
Bristol Myers Squibb charges U.S. patients $7,100 for blood thinner Eliquis, but sells the same product for $900 in Canada and just $650 in France, he said. Merck charges U.S. diabetes patients $6,900 for Januvia when that same product is only $900 in Canada and $200 in France, he added.
Sanders said that, despite discussions about how divided the nation is over many issues, one matter that people agree on is “the need to substantially lower the outrageously high price of prescription drugs in our country.” He cited an unspecified recent poll showing that 82% of Americans said the cost of prescription drugs is too high, with 73% saying the government is not doing enough to regulate drug prices.
Sanders charged that drugmakers are spending billions of dollars on executive compensation, stock buybacks as well as mergers and acquisitions, and passing the costs onto patients.
"Americans are forced to pay higher and higher prices for the drugs they need to survive," Sanders said. "And let's be clear, the overwhelming beneficiary of these high drug prices is the pharmaceutical industry."
Pricey insulin costs
In a separate announcement on February 1, the Health and Human Services’ (HHS) Office of the Assistant Secretary for Planning and Evaluation (ASPE) issued several reports with cost comparisons of prescription drugs in the U.S. versus those in other Organisation for Economic Co-operation and Development (OECD) countries.
Among ASPE's findings was the fact that U.S. prices for all branded and generic drugs in 2022 were nearly 3 times as high as those in 33 of the OECD countries.
“For every dollar paid in other countries for drugs, consumers in the United States pay $2.78,” according to the report. “The gap is widening over time as U.S. drug prices grow faster than drug prices in other countries and the mix of drugs changes.”
The U.S. gross prices for insulin — which was developed about 100 years ago and costs drugmakers about $10 a vial to produce — were on average nearly 10 times the price in the U.S. than they were in 33 OECD countries as well, said the Biden administration citing the report.
New website for beneficiaries
HHS has launched LowerDrugCosts.gov, a new website for Medicare beneficiaries with information related to the drug pricing provisions of the Inflation Reduction Act as well as resources for Medicare enrollees and other interested parties.
Related Content
-
Stocks Slide to Start September: Stock Market TodaySeasonal trends suggest tough times for the stock market as we round into the end of the third quarter.
-
Here's What You'd Have If You Invested $1,000 Into Sherwin-Williams 20 Years AgoSherwin-Williams stock has clobbered the broader market by a wide margin for a long time.
-
The Unsung Hero of Aisle 5: A Tale of Forgotten Change and Compassion at the SupermarketThis supermarket manager went above and beyond to help when a child forgot her change at the checkout counter. You might be surprised at some of the complications that supermarkets face when it comes to customers' forgotten change.
-
Train, Integrate, Retain: A Strategic Playbook for Adviser OnboardingsBuild a thriving practice by training new advisers with clear goals, structured processes and consistent mentorship for strong team growth.
-
Why is My First Medicare Bill So High?Your first Medicare bill may be higher than expected for several reasons. If your premiums aren't taken out of your Social Security benefit, the bill can be huge.
-
11 Unforgettable Road Trips to Take in RetirementMore than a travel trend, the road trip is a quintessential American tradition, with millions of us taking them each year. Here's a guide to helping you choose your next adventure.
-
I'm a Financial Professional: Here Are Four Ways You Can Use Debt to Build WealthUsing debt strategically, such as for homeownership, education and more, can lead to greater financial stability and growth.
-
Five Key Wake-Up Calls for Ambitious Business Owners, From a Biz SpecialistYour personal financial plan needs to include a formal exit strategy for your business, or you could be in trouble.
-
4 Career Moves to Make Now if You're Worried About a RecessionWorried about a recession? These steps to protect your job prospects will help you professionally whether a downturn develops or not.
-
How StoryCorps Works and How You Can Tell Your StoryStoryCorps has recorded conversations between thousands of people, and anyone can participate. National facilitator Alan Jinich explains how to share your story.
